P2RY12 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL315473	1.00	20/20
SCHEMBL316581	1.00	20/20
SCHEMBL316582	1.00	20/20
SCHEMBL316809	1.00	20/20
SCHEMBL316810	1.00	20/20
SCHEMBL317088	1.00	20/20
SCHEMBL317089	1.00	20/20
SCHEMBL317193	1.00	20/20
SCHEMBL317194	1.00	20/20
SCHEMBL316800	0.98	20/20
SCHEMBL316801	0.98	20/20
SCHEMBL317163	0.93	20/20
SCHEMBL317164	0.93	20/20
SCHEMBL317649	0.93	20/20
SCHEMBL317650	0.93	20/20
SCHEMBL316615	0.90	20/20
SCHEMBL316616	0.90	20/20
SCHEMBL316734	0.90	20/20
SCHEMBL316735	0.90	20/20
SCHEMBL315993	0.89	20/20

Clinical trials — most relevant to P2RY12 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment	PHASE4	COMPLETED
Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI	PHASE4	UNKNOWN
Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI	PHASE4	COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest	PHASE4	UNKNOWN
Reversal of the Anti-platelet Effects of Ticagrelor	PHASE4	COMPLETED
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study	PHASE4	COMPLETED
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR	PHASE4	NOT_YET_RECRUITING
Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES	PHASE4	UNKNOWN
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease	PHASE4	COMPLETED
Clopidogrel and Response Variability Investigation Study 2	PHASE3	COMPLETED
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease	PHASE2/PHASE3	COMPLETED
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.	PHASE2	COMPLETED
Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention	PHASE2	UNKNOWN
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy	PHASE2	RECRUITING
Cell Therapy in Critical Limb Ischemia	PHASE2	UNKNOWN
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects	PHASE1	COMPLETED
A Genomic Approach for Clopidogrel in Caribbean Hispanics	EARLY_PHASE1	COMPLETED
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention	nan	COMPLETED
Platelet Function in Resuscitated Patients	nan	COMPLETED
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES	nan	UNKNOWN
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)	nan	ACTIVE_NOT_RECRUITING
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence	nan	COMPLETED
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes	nan	COMPLETED
Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia	nan	RECRUITING
Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome	nan	COMPLETED
Study of AggreGuide A-100 (ADP) Assay	nan	COMPLETED
Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)	nan	COMPLETED
CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA)	nan	NOT_YET_RECRUITING
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RY12 binder may also engage these)

Protein	Name	Similarity
Q9CPV9	—	1.000	Q9CPV9 →
Q95KC3	—	1.000	Q95KC3 →
Q9ESG6	—	1.000	Q9ESG6 →
Q9EPX4	—	0.999	Q9EPX4 →
O35881	—	0.995	O35881 →
Q3SX17	—	0.994	Q3SX17 →
P2RY14	P2Y purinoceptor 14	0.992	landscape →
D4A4Q2	—	0.985	D4A4Q2 →
Q3ZBK9	—	0.981	Q3ZBK9 →
O14626	—	0.981	O14626 →
Q9BY21	—	0.981	Q9BY21 →
Q99MT7	—	0.980	Q99MT7 →
Q8BG55	—	0.979	Q8BG55 →
Q4G072	—	0.979	Q4G072 →
Q8BLG2	—	0.979	Q8BLG2 →
LPAR4	Lysophosphatidic acid receptor 4	0.977	landscape →
Q924T8	—	0.973	Q924T8 →
P55086	—	0.972	P55086 →
LPAR6	Lysophosphatidic acid receptor 6	0.972	landscape →
Q9R1K6	—	0.971	Q9R1K6 →
P32250	—	0.970	P32250 →
F2RL1	Proteinase-activated receptor 2	0.969	landscape →
Q80Z39	—	0.969	Q80Z39 →
Q924T9	—	0.967	Q924T9 →
Q2HJA4	—	0.967	Q2HJA4 →
P49652	—	0.967	P49652 →
Q2NNR5	—	0.967	Q2NNR5 →
Q8BMC0	—	0.967	Q8BMC0 →
CYSLTR1	Cysteinyl leukotriene receptor 1	0.967	landscape →
HCAR2	Hydroxycarboxylic acid receptor 2	0.966	landscape →